Elevation Oncology, Inc. Expected to Post Q3 2024 Earnings of ($0.20) Per Share (NASDAQ:ELEV)

Elevation Oncology, Inc. (NASDAQ:ELEV) – Wedbush raised their Q3 2024 earnings estimates for shares of Elevation Oncology in a report issued on Tuesday, August 6th. Wedbush analyst R. Driscoll now forecasts that the company will earn ($0.20) per share for the quarter, up from their prior estimate of ($0.22). Wedbush currently has a “Outperform” rating and a $8.00 price objective on the stock. The consensus estimate for Elevation Oncology’s current full-year earnings is ($0.92) per share. Wedbush also issued estimates for Elevation Oncology’s Q4 2024 earnings at ($0.21) EPS, FY2024 earnings at ($0.81) EPS, Q1 2025 earnings at ($0.16) EPS, Q2 2025 earnings at ($0.15) EPS, Q3 2025 earnings at ($0.16) EPS, Q4 2025 earnings at ($0.17) EPS and FY2025 earnings at ($0.64) EPS.

Elevation Oncology (NASDAQ:ELEV) last posted its earnings results on Tuesday, August 6th. The company reported ($0.18) EPS for the quarter, beating the consensus estimate of ($0.23) by $0.05.

A number of other equities analysts also recently issued reports on ELEV. Piper Sandler started coverage on Elevation Oncology in a report on Friday, May 31st. They issued an “overweight” rating and a $10.00 price target for the company. Stephens started coverage on shares of Elevation Oncology in a research report on Tuesday, May 14th. They set an “overweight” rating and a $8.00 price objective for the company. JMP Securities reaffirmed a “market outperform” rating and issued a $7.00 target price on shares of Elevation Oncology in a research report on Monday, July 15th. Finally, HC Wainwright reissued a “buy” rating and issued a $6.00 price target on shares of Elevation Oncology in a research report on Wednesday. Five investment analysts have rated the stock with a buy rating, According to MarketBeat, the company currently has a consensus rating of “Buy” and an average target price of $7.80.

Elevation Oncology Trading Up 7.2 %

NASDAQ:ELEV opened at $0.78 on Friday. The company has a debt-to-equity ratio of 0.41, a quick ratio of 46.22 and a current ratio of 46.22. Elevation Oncology has a 1 year low of $0.36 and a 1 year high of $5.83. The stock has a market cap of $42.48 million, a P/E ratio of -0.75 and a beta of 1.38. The stock has a 50-day simple moving average of $2.71 and a 200-day simple moving average of $3.45.

Institutional Investors Weigh In On Elevation Oncology

Several large investors have recently modified their holdings of ELEV. SG Americas Securities LLC purchased a new stake in shares of Elevation Oncology in the first quarter valued at about $63,000. American Century Companies Inc. increased its position in Elevation Oncology by 55.7% in the 2nd quarter. American Century Companies Inc. now owns 49,222 shares of the company’s stock valued at $133,000 after acquiring an additional 17,602 shares during the period. Rhumbline Advisers purchased a new stake in Elevation Oncology during the 2nd quarter valued at approximately $175,000. Bank of New York Mellon Corp purchased a new stake in Elevation Oncology during the 2nd quarter valued at approximately $415,000. Finally, Vanguard Group Inc. lifted its position in Elevation Oncology by 30.8% during the 1st quarter. Vanguard Group Inc. now owns 1,532,045 shares of the company’s stock worth $7,859,000 after acquiring an additional 360,799 shares during the period. 83.70% of the stock is owned by institutional investors and hedge funds.

Elevation Oncology Company Profile

Elevation Oncology, Inc, an oncology company, focuses on the discovery and development of cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs. The company's lead candidate is EO-3021, an antibody-drug conjugate designed to target Claudin 18.2, a clinically validated molecular target.